- Prestige Consumer Healthcare to Release Fiscal 2025 First Quarter Earnings Results
- Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference
- Prestige Consumer Healthcare Inc. Reports Fiscal Year 2024 Results
- Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarter and Year-End Earnings Results
- Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag
- Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 1% Tolnaftate Athlete’s Foot Spray Antifungal Spray Liquid Due to the Presence of Benzene
- Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter Earnings Results
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of Americaine® 20% Benzocaine Topical Anesthetic Spray Due to the Presence of Benzene
- Insight Pharmaceuticals Issues Voluntary Nationwide Recall of TING® 2% Miconazole Nitrate Athlete’s Foot Spray Antifungal Spray Powder Due to the Presence of Benzene
More ▼
Key statistics
As of last trade Prestige Consumer Healthcare Inc (PBH:NYQ) traded at 67.37, -10.54% below its 52-week high of 75.31, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 68.50 |
---|---|
High | 68.50 |
Low | 67.31 |
Bid | 67.30 |
Offer | 67.40 |
Previous close | 68.28 |
Average volume | 338.75k |
---|---|
Shares outstanding | 49.92m |
Free float | 49.25m |
P/E (TTM) | 16.37 |
Market cap | 3.41bn USD |
EPS (TTM) | 4.17 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 17:00 BST.
More ▼